Lupus therapeutic products provide relief from the symptoms and complications associated with lupus. The products available are corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, immunosuppressants and biologics. Corticosteroids help reduce joint swelling, pain and inflammation. NSAIDs aid in reducing fever and pain. Antimalarials are used for skin and joint problems. Immunosuppressants suppress the immune system to minimize symptoms. Biologics target specific components of the immune system.
The global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing research and development activities for developing novel biologic therapies is one of the key trends in the global lupus therapeutic market. Various biotechnology and pharmaceutical companies are conducting clinical trials to develop targeted biologic therapies with high efficacy and fewer side effects. For instance, Anthropic, PBC is conducting clinical trials for its AI-based drug candidate called Pretronix which selectively targets B cells that trigger lupus. Similarly, Aurinia Pharmaceuticals Inc. has received FDA approval for Lupkynis (voclosporin), a novel oral therapy targeting T cell mediated inflammation for the treatment of lupus nephritis. Such ongoing research and development activities are expected to push the market growth over the forecast period.
Segment Analysis
The global lupus therapeutic market is segmented by drug class, route of administration, distribution channel and geography. Based on drug class, the market is segmented into corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, immunosuppressants and others. Amongst these, the immunosuppressants segment dominates the market owing to their high usage in treating lupus. These drugs act by suppressing the immune system thereby reducing inflammation in the body.
Key Takeaways
Global Lupus Therapeutic Market Demand is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the market owing to high awareness levels about lupus, presence of key market players and established healthcare infrastructure in the region. Asia Pacific is expected to witness fastest growth during the forecast period due to rising incidences of lupus, rise in healthcare spending and growing focus of key players.
Key players: Key players operating in the lupus therapeutic market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC and Aurinia Pharmaceuticals, Inc. GlaxoSmithKline plc dominates the market owing to its broad product portfolio and high brand recognition. The company focuses on partnerships and new product launches to strengthen its position in the market.
Get More insights on this Topic- https://www.dailyprbulletin.com/lupus-therapeutic-market-future-trends-and-value-insights/
Check Below Trending Articles on related Topic- https://allmeaninginhindi.com/guardians-of-code-fortifying-your-application-against-digital-intruders/
Comments
0 comment